Avivagen (VIVXF) Stock Price, News & Analysis

Company Overview

Avivagen Inc. is a life sciences company headquartered in Ottawa, Ontario, specializing in the development of novel feed additives for the animal health market. The company’s flagship technology, known as OxC-beta™, is designed to promote a balanced immune response in food-producing animals through the controlled oxidation of unsaturated fatty acids. By enhancing natural defenses, Avivagen aims to reduce reliance on antibiotic growth promoters and address consumer demand for antibiotic-free meat and poultry products.

The company’s product pipeline targets key agricultural sectors, including poultry, swine and ruminants. OxC-beta™ formulations are currently undergoing trials and commercial evaluations in North and South America, with partnerships in place to facilitate distribution and on-farm demonstration programs. Avivagen’s approach focuses on feed supplementation strategies that integrate seamlessly into existing production systems, offering producers a tool to improve animal performance, health and overall farm sustainability.

Founded in the early 2010s, Avivagen draws on expertise from nutritional science and immunology research. It has established collaborations with academic institutions and contract research organizations to advance development and regulatory approvals. The company is led by Chief Executive Officer Steven Bromley, who oversees strategy, research collaborations and commercialization efforts as Avivagen seeks to expand its market presence and support global efforts to curb antibiotic use in livestock production.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

VIVXF Stock Analysis - Frequently Asked Questions

How do I buy shares of Avivagen?

Shares of VIVXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/19/2025
• Fiscal Year End: 10/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:VIVXF
• CIK: N/A
• Web: www.avivagen.com
• Phone: 613-702-2908
• Fax: N/A
• Employees: 13
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $730 thousand
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A